Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
July 18, 2018Expert Review of Anticancer Therapy

The role of prostate cancer antigen 3 (PCA3) in prostate cancer detection

View Full Paper
Ask AI
Bookmark
Share

Authors

GPGuillaume PloussardHôpital de la Croix-RousseATAlexandre de la TailleCentre Hospitalier Universitaire Henri-Mondor

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Ploussard et al. (2018) studied this question.

synapsesocial.com/papers/69d8fe158c03fbaff8bf0323https://doi.org/10.1080/14737140.2018.1502086
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Prognostic value of urinary prostate cancer antigen 3 (PCA3) during active surveillance of patients with low‐risk prostate cancer receiving 5α‐reductase inhibitors2017 · 13 citations
  2. 2Clinical Evaluation of the PCA3 Assay in Guiding Initial Biopsy Decisions2011 · 150 citations
  3. 3The clinical effectiveness and cost-effectiveness of the PROGENSA® prostate cancer antigen 3 assay and the Prostate Health Index in the diagnosis of prostate cancer: a systematic review and economic evaluation2015 · 78 citations
  4. 4Can Urinary PCA3 Supplement PSA in the Early Detection of Prostate Cancer?2014 · 278 citations